How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

162 results for

Cyclic Lipopeptide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Characterization of two antimicrobial peptides produced by a halotolerant Bacillus subtilis strain SK.DU.4 isolated from a rhizosphere soil sample Full Text available with Trip Pro

as a cyclic lipopeptide with a β-hydroxy fatty acid linked to Ser of a peptide with seven α-amino acids (Asp-Tyr-Asn-Gln-Pro-Asn-Ser) and assigned it to iturin-like group of antimicrobial biosurfactants. However, it differed in amino acid composition with other members of the iturin family. Both peptides were active against Gram-positive bacteria, suggesting that they had an additive effect. (...) of chemical extraction and chromatographic techniques. The MALDI-TOF analysis of HPLC purified fractions revealed that the strain SK.DU.4 secreted a bacteriocin-like peptide with molecular mass of 5323.9 Da and a surface-active lipopeptide (m/z 1056 Da). The peptide mass fingerprinting of low-molecular-weight bacteriocin exhibited significant similarity with stretches of secreted lipoprotein of Methylomicrobium album BG8 and displayed 70% sequence coverage. MALDI MS/MS analysis elucidated the lipopeptide

2013 AMB Express

102. Biosynthetic Multitasking Facilitates Thalassospiramide Structural Diversity in Marine Bacteria Full Text available with Trip Pro

Biosynthetic Multitasking Facilitates Thalassospiramide Structural Diversity in Marine Bacteria Thalassospiramides A and B are immunosuppressant cyclic lipopeptides first reported from the marine α-proteobacterium Thalassospira sp. CNJ-328. We describe here the discovery and characterization of an extended family of 14 new analogues from four Tistrella and Thalassospira isolates. These potent calpain 1 protease inhibitors belong to six structure classes in which the length and composition

2013 Journal of the American Chemical Society

103. Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection

of the peritoneal membrane. Based on the recommendations of the International Society for Peritoneal Dialysis, the intraperitoneal route is preferentially recommended. For many antibiotics, pharmacokinetics (intravenous and intraperitoneal) was studied and protocols for IP administration were validated. Daptomycin, is a cyclic lipopeptide natural, active only on Gram-positive bacteria. It is presented as an alternative to vancomycin in infections resistant pathogens. The stability of daptomycin in peritoneal

2013 Clinical Trials

104. Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 2

Bacteremia Drug: Daptomycin Drug: Comparator Phase 4 Detailed Description: S. aureus causes a series of invasive diseases in adults and children, including bacteremia. Infections due to S. aureus in children, particularly those due to methicillin resistant S. aureus (MRSA), are a growing world-wide public health concern. Daptomycin, a cyclic lipopeptide antibacterial agent, shows rapid in vitro bactericidal activity with concentration-dependent killing for Gram-positive organisms, including S. aureus

2012 Clinical Trials

105. Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis Full Text available with Trip Pro

Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Daptomycin is a cyclic lipopeptide that is approved to treat S aureus bacteremia and right-sided endocarditis, and reports of S aureus with reduced susceptibility to daptomycin are infrequent

2012 The Canadian Journal of Infectious Diseases & Medical Microbiology

106. Lyngbyabellins K-N from Two Palmyra Atoll Collections of the Marine Cyanobacterium Moorea bouillonii Full Text available with Trip Pro

Lyngbyabellins K-N from Two Palmyra Atoll Collections of the Marine Cyanobacterium Moorea bouillonii Five lipopeptides of the lyngbyabellin structure class, four cyclic (1-3, and 5) and one linear (4), were isolated from the extracts of two collections of filamentous marine cyanobacteria obtained from Palmyra Atoll in the Central Pacific Ocean. Their planar structures and absolute configurations were elucidated by combined spectroscopic and chromatographic analyses as well as chemical synthesis

2012 European journal of organic chemistry

107. β-lactams increase the antibacterial activity of daptomycin against clinical MRSA strains and prevent selection of DAP-resistant derivatives. Full Text available with Trip Pro

β-lactams increase the antibacterial activity of daptomycin against clinical MRSA strains and prevent selection of DAP-resistant derivatives. Methicillin-resistant Staphylococcus aureus (MRSA) has emerged to be one of the most important pathogens both in health care and in community-onset infections. Daptomycin (DAP) is a cyclic anionic lipopeptide recommended for treatment of skin infections, bacteremia, and right-sided endocarditis caused by MRSA. Resistance to DAP (DAP(r)) has been reported

2012 Antimicrobial Agents and Chemotherapy

108. Daptomycin

of Washington School of Pharmacy Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Daptomycin is a cyclic lipopeptide that has a unique mechanism of action. It binds to the bacterial cell membranes, causing rapid depolarization of the membrane due to potassium efflux and associated disruption of DNA, RNA, and protein synthesis; the result is rapid concentration-dependent bacterial death (see ). Indications Daptomycin has activity against the following: Gram-positive

2013 Merck Manual (19th Edition)

109. Occidiofungin's Chemical Stability and In vitro Potency Against Candida species. Full Text available with Trip Pro

Occidiofungin's Chemical Stability and In vitro Potency Against Candida species. Occidiofungin is a cyclic glyco-lipopeptide produced by Burkholderia contaminans. MICs against Candida species were between 0.5 and 2.0 μg/ml. Occidiofungin retains its in vitro potency in the presence of 5% and 50% human serum with a minimal lethal concentration (MLC) of 2 and 4 μg/ml, respectively. Time-kill and postantifungal effect (PAFE) experiments of occidiofungin against Candida albicans were performed

2011 Antimicrobial Agents and Chemotherapy

110. Daptomycin Antibiotic-Lock Therapy in a Rat Model of Staphylococcal Central Venous Catheter Biofilm Infections. Full Text available with Trip Pro

Daptomycin Antibiotic-Lock Therapy in a Rat Model of Staphylococcal Central Venous Catheter Biofilm Infections. Antibiotic lock therapy (ALT) is an adjunctive procedure to prevent or treat central venous catheter infections, ensuing catheter-related bacteremia, and catheter-related metastatic infections. Daptomycin is a cyclic lipopeptide that is rapidly bactericidal against methicillin-susceptible and -resistant Staphylococcus aureus. The efficacies of daptomycin against central venous

2011 Antimicrobial Agents and Chemotherapy

111. Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Full Text available with Trip Pro

Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Daptomycin (DAP) is a cyclic lipopeptide that disrupts the functional integrity of the cell membranes of Gram-positive bacteria in a Ca(2+)-dependent manner. Here we present genetic, genomic, and phenotypic analyses of an evolved DAP-resistant isolate, Dap(R)1, from the model bacterium Bacillus subtilis 168. Dap(R)1 was obtained by serial passages with increasing DAP concentrations, is 30

2011 Antimicrobial Agents and Chemotherapy

112. Antibacterial Full Text available with Trip Pro

in or clinical trials. These drugs however, did not address the entire spectrum of resistance of GNB. According to the WHO fifty one new therapeutic entities (NTEs) - antibiotics (including combinations), are in phase 1-3 clinical trials as of May 2017. Recent entries in the clinical pipeline targeting multidrug-resistant Gram-positive pathogens has improved the treatment options due to marketing approval of new antibiotic classes, the oxazolidinones and cyclic lipopeptides. However, resistance (...) ( , , , and ) have activities. ( , , and ) are usually (with the exception of bactericidal ). Further categorization is based on their target specificity. "Narrow-spectrum" antibiotics target specific types of bacteria, such as or , whereas affect a wide range of bacteria. Following a 40-year break in discovering new classes of antibacterial compounds, four new classes of antibiotics have been brought into clinical use in the late 2000s and early 2010s: cyclic

2012 Wikipedia

113. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Full Text available with Trip Pro

A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Polymyxins are cationic lipopeptides (five cationic charges) and the last resort for the treatment of serious Gram-negative infections caused by multiresistant strains. NAB741 has a cyclic peptide portion identical to that of polymyxin B but carries in the linear peptide portion a threonyl-D-serinyl residue (no cationic

2010 Antimicrobial Agents and Chemotherapy

114. Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)

of Vienna Information provided by: Medical University of Vienna Study Details Study Description Go to Brief Summary: The purpose of this trial is to study the pharmacokinetics of anidulafungin during continuous venovenous hemofiltration. Background: Anidulafungin is a cyclic lipopeptide antifungal agent of the echinocandin class. Members of this class of antifungal agents are known to inhibit the synthesis of glucan polymers in fungal cell walls. The spectrum of activity of anidulafungin includes

2009 Clinical Trials

115. Effects of Supported Lipid Monolayer Fluidity on the Adhesion of Hematopoietic Progenitor Cell Lines to Fibronectin-Derived Peptide Ligands for α5β1 and α4β1 Integrins Full Text available with Trip Pro

is an important ECM component in many tissues, including the hematopoietic stem cell niche. We examined the adhesion of the M07e and THP-1 hematopoietic progenitor cell lines to fibronectin-derived peptide ligands for the alpha5beta1 (cyclic and linear RGD) and alpha4beta1 (cyclic LDV) integrins as well as the heparin-binding domain (HBD) presented as lipopeptides in fluid and gel SLMs. M07e cells adhered more avidly than THP-1 cells to all of the lipopeptides in fluid and gel surfaces. The adhesion of both (...) cell lines to all peptides was less avid in fluid versus gel SLMs. Adhesion to cyclic LDV (cLDV) and cRGD was similar on gel SLMs for both cell lines. In contrast, adhesion to cLDV was less extensive than to cRGD in fluid SLMs, especially for M07e cells. Adhesion to linear RGD was less avid than to cRGD or cLDV and decreased to a greater extent in fluid SLMs. Human aortic endothelial cells adhered to cRGD in fluid SLMs and remained viable for at least 24 h but did not spread. We also showed

2009 Langmuir : the ACS journal of surfaces and colloids

116. Cellular Responses of the Late Blight Pathogen Phytophthora infestans to Cyclic Lipopeptide Surfactants and Their Dependence on G Proteins Full Text available with Trip Pro

Cellular Responses of the Late Blight Pathogen Phytophthora infestans to Cyclic Lipopeptide Surfactants and Their Dependence on G Proteins Oomycete pathogens cause major yield losses for many crop plants, and their control depends heavily on agrochemicals. Cyclic lipopeptides (CLPs) were recently discovered as a new class of natural compounds with strong activities against oomycetes. The CLP massetolide A (Mass A), produced by Pseudomonas fluorescens, has zoosporicidal activity, induces

2009 Applied and environmental microbiology

117. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Full Text available with Trip Pro

Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Daptomycin is a new intravenous cyclic lipopeptide antibiotic, licensed for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms including both susceptible and resistant strains of Staphylococcus aureus and for the treatment of various infections due to susceptible organisms, including serious and life-threatening Gram

2009 Transplantation

118. The Lipopeptide Antibiotic Friulimicin B Inhibits Cell Wall Biosynthesis through Complex Formation with Bactoprenol-Phosphate. Full Text available with Trip Pro

The Lipopeptide Antibiotic Friulimicin B Inhibits Cell Wall Biosynthesis through Complex Formation with Bactoprenol-Phosphate. Friulimicin B is a naturally occurring cyclic lipopeptide, produced by the actinomycete Actinoplanes friuliensis, with excellent activity against gram-positive pathogens, including multidrug-resistant strains. It consists of a macrocyclic decapeptide core and a lipid tail, interlinked by an exocyclic amino acid. Friulimicin is water soluble and amphiphilic

2009 Antimicrobial Agents and Chemotherapy

119. Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis to Daptomycin. Full Text available with Trip Pro

Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis to Daptomycin. Daptomycin is the first of a new class of cyclic lipopeptide antibiotics used against multidrug-resistant, gram-positive pathogens. The proposed mechanism of action involves disruption of the functional integrity of the bacterial membrane in a Ca(2+)-dependent manner. We have used transcriptional profiling to demonstrate that treatment of Bacillus subtilis with daptomycin strongly induces the lia operon

2009 Antimicrobial Agents and Chemotherapy

120. Cubicin - daptomycin

problems due to acquisition of multiple resistance determinants. Therefore, there is a need for additional agents that might be clinically active against these difficult to treat pathogens to the existing antibiotic armamentarium. The present application for marketing authorisation of CUBICIN (350 or 500 mg powder for concentrate for solution for infusion) is made under Article 8.3 (i) and concerns a new active substance, daptomycin. Daptomycin is a novel cyclic lipopeptide derived from a natural (...) pharmacodynamics Daptomycin is a novel cyclic lipopeptide antibiotic derived from the fermentation of a strain of Streptomyces roseosporus. Daptomycin inserts directly into the cytoplasmic membrane of Gram-positive cells (aerobes and anaerobes). This action is calcium-dependent and results in a rapid depolarisation of the membrane, thus giving rise to the efflux of potassium ions. Bacterial DNA, RNA and protein synthesis is rapidly stopped with subsequent cell death that does not depend upon lysis

2006 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>